Company announcement - No. 12/2017
Zealand announces information received from its major shareholder Lønmodtagernes Dyrtidsfond (LD)
Copenhagen, April 27, 2017 - Zealand announces that it has received information from its major shareholder, Lønmodtagernes Dyrtidsfond (LD), that they have sold shares in Zealand Pharma reducing their holding to below 5% of Zealand outstanding shares.
Kristoffer Fabricius Birch, Head of Equities, Lønmodtagernes Dyrtidsfond (LD) commented: "Lønmodtagernes Dyrtidsfond (LD) has been one of the largest shareholders in Zealand Pharma since 2000 when LD invested in Zealand Pharma as an unlisted company. LD has enjoyed a good return and expect to continue to do that in the future. LD has today slightly reduced its holding in Zealand Pharma purely as part of LD's ongoing risk management."
For further information, please contact:
Mats Blom, Senior Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases.
2
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua(TM) 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe.
Zealand's pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).